Background: There is conflicting evidence regarding the prognostic value of cytotoxic T cell
infiltration in breast cancer. The aims of this study were to detect the expression levels and …

Breast cancer is one of the leading causes of cancer death in women worldwide due to its
variable aggressiveness and high propensity to develop distant metastases. The staging …

Background The prognostic value of syndecan-1 (SDC1, also called CD138) in breast
cancer remains controversial. Therefore, we performed a meta-analysis to assess the …

Background A majority of breast cancer tumors express estrogen receptor (ER) and/or
progesterone receptor (PR); however, the percentage of cancer cells expressing these …

The aim of this study was to evaluate the prognostic impact that hormone receptor (HR)
expressions have on the two different breast cancer (BC) entities—multifocal versus unifocal …

Progesterone-Receptor (PR) positivity is related with an enhanced response to breast
cancer therapy, conversely cyclin D1 (CD1) is a retained marker of poor outcome. Herein …

Background Despite initial indications that the transcription factor Twist could be used as a
breast cancer prognostic marker, there still exists some controversy about its reliability. Thus …

Background Several studies have demonstrated that stromal cell derived factor-1 (SDF1,
also known as CXCL12) expression is a biomarker for breast cancer treatment; however, its …

Introduction In luminal-like early breast cancer (BC), the lack of Progesterone Receptor (PR)
expression generally correlates with more aggressive behavior but the clinical validity of low …

Background: In the Italian Breast Cancer Intergroup Studies (IBIS) 3 phase III trial, we
compared cyclophosphamide, methotrexate, 5-fluorouracil (CMF) alone to sequential …